期刊
PHARMACEUTICALS
卷 14, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/ph14040316
关键词
thymic epithelial tumors; thymoma; thymic carcinoma; thymic neuroendocrine tumors; targeted therapy; molecular; biology; genomic; biomarkers; next-generation sequencing
Thymic tumors consist of three histological subtypes with completely different clinical behaviors: thymic carcinomas, thymomas, and thymic neuroendocrine tumors. Recent clinical trials have shown some encouraging results, presenting promising targeted therapies for thymic tumors.
Thymic tumors are a group of rare mediastinal malignancies that include three different histological subtypes with completely different clinical behavior: the thymic carcinomas, the thymomas, and the rarest thymic neuroendocrine tumors. Nowadays, few therapeutic options are available for relapsed and refractory thymic tumors after a first-line platinum-based chemotherapy. In the last years, the deepening of knowledge on thymus' biological characterization has opened possibilities for new treatment options. Several clinical trials have been conducted, the majority with disappointing results mainly due to inaccurate patient selection, but recently some encouraging results have been presented. In this review, we summarize the molecular alterations observed in thymic tumors, underlying the great biological differences among the different histology, and the promising targeted therapies for the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据